

1991 INDEX

A

- Adenocarcinoma: of lung, Mar./Apr. 85-86
- Alkaline phosphatase: placental, as tumor marker, Nov./Dec. 330-331
- Allele losses: at multiple sites in lung cancer, Mar./Apr. 71
- Alpha-fetoprotein
 - elevation in various diseases, Nov./Dec. 314
 - in germ cell tumors, Nov./Dec. 316
 - screening results, Nov./Dec. 315
 - as tumor marker, Nov./Dec. 313-317
- Antigen(s)
 - cancer, mucinous-like, as tumor marker, Nov./Dec. 323-324
 - carcinoembryonic (see Carcinoembryonic antigen)
 - carcinoma, squamous cell, as tumor marker, Nov./Dec. 318
 - Lewis, and mucin-glycoprotein epitopes, Nov./Dec. 321
 - prostate specific, as tumor marker, Nov./Dec. 318-320
 - tissue polypeptide, as tumor marker, Nov./Dec. 317
- Asbestos: and lung cancer, Mar./Apr. 68-69
- Assays: of hormone receptor, comparison of, July/Aug. 172

B

- B-cell lymphoma: after marrow transplant, Jan./Feb. 40-41
- Beta-2-microglobulin: as tumor marker, Nov./Dec. 335-338
- Biopsy: percutaneous fine-needle aspiration, in lung cancer, Mar./Apr. 82-83
- Bone marrow (see Marrow)
- Breast cancer-associated mucinous glycoproteins, Nov./Dec. 323-324

as tumor markers, Nov./Dec. 323-324

- Breast cancer, early stage, July/Aug. 161-232
 - abstract, July/Aug. 161-162
 - chemotherapy of, adjuvant, July/Aug. 183-200
 - drug regimen, optimal, July/Aug. 191-192
 - duration of, optimal, July/Aug. 193-194
 - IBSCG Trial, July/Aug. 187
 - Intergroup Trial, July/Aug. 187-188
 - Milan Trial, July/Aug. 186-187
 - NSABP B-13 in, July/Aug. 188
 - regimens for, selection of, July/Aug. 194-195
 - single-agent vs. combination, July/Aug. 192-193
 - studies of, July/Aug. 183-188
 - toxicity of, July/Aug. 198-200
 - trials of, July/Aug. 184-185
- chemotherapy, dose intensity, July/Aug. 188-190
- DNA ploidy and, July/Aug. 176-178
- endocrine treatment, July/Aug. 200-214
 - historical perspective, July/Aug. 200-202
 - new therapies, July/Aug. 213-214
- genetic alterations in, July/Aug. 178-181
- growth factor receptors in, July/Aug. 178-181
- hormone
 - receptor status, determination and significance, July/Aug. 170-174
 - replacement, regulation and pregnancy in, July/Aug. 174-176
- medical management, July/Aug. 161-232

Breast cancer (cont.)

- multimodality treatment, sequencing of, July/Aug. 195-198
- oncogenes in, July/Aug. 178-181
- posttherapy evaluations, July/Aug. 214-215
- prognostic factors, July/Aug. 162-183
 - application of, July/Aug. 181-183
 - histology in, July/Aug. 169-170
 - metastases extent in, July/Aug. 166-169
 - overview of, July/Aug. 182
 - proliferative fraction in, July/Aug. 176-178
 - recurrence in, local, July/Aug. 163-165
 - size of tumor in, July/Aug. 166-169
- tamoxifen in, July/Aug. 202-207, 210-211
- trials, July/Aug. 203
- Breast cancer: marrow transplant in, Jan./Feb. 35-36
- Bronchioloalveolar carcinoma characteristics of, Mar./Apr. 76-77
- pathology, Mar./Apr. 85-86
- Bronchoscopy: fiberoptic, in lung cancer detection, Mar./Apr. 81-82

C

- CA 15-3: as tumor marker, Nov./Dec. 322
- CA 19-9: as tumor marker, Nov./Dec. 324-326
- CA 50: as tumor marker, Nov./Dec. 324-326
- CA 125: as tumor marker, Nov./Dec. 327-328
- CA 195: as tumor marker, Nov./Dec. 326-327
- Calcitonin: as tumor marker, Nov./Dec. 331
- Cancer
 - antigen, mucinous-like, as tumor marker, Nov./Dec. 323-324
 - breast (see Breast cancer)
 - colon, CEA elevation in, Nov./Dec. 308
 - esophageal (see Esophagus, cancer)
 - gastric (see Gastric cancer)
 - gastrointestinal tract (see Gastrointestinal tract cancer)
 - hematological, marrow transplant in, Jan./Feb. 19-33
 - lung (see Lung cancer)
 - ovarian, marrow transplant in, Jan./Feb. 36
 - pancreas, CA 19-9 in, Nov./Dec. 325
 - testicular, marrow transplant in, Jan./Feb. 34-35
- Carboplatin
 - in esophageal cancer, Sept./Oct. 259
 - in marrow transplant, Jan./Feb. 13
- Carcinoembryonic antigen concentrations in sera, Nov./Dec. 306
- elevated
 - in colon cancer, Nov./Dec. 308
 - conditions associated with, Nov./Dec. 305
 - studies using, summary of, Nov./Dec. 310-311
 - as tumor marker, Nov./Dec. 304-313
- Carcinogens: and lung cancer, Mar./Apr. 68-69
- Carcinoma
 - bronchioloalveolar
 - characteristics, Mar./Apr. 76-77
 - pathology, Mar./Apr. 85-86
 - esophagus (see Esophagus, carcinoma)
 - lung (see Lung carcinoma)
 - squamous cell, antigen as tumor marker, Nov./Dec. 318
- Catecholamines: as tumor marker, Nov./Dec. 333-334
- Cell(s)
 - germ cell tumors, Nov./Dec. 316
 - stem (see Stem cells)
- Cerebral metastasis: solitary, in lung cancer, May/June 117

Chemohormonal treatment: in breast cancer, July/Aug. 207-210

Chemotherapy
 in breast cancer (*see* Breast cancer, early stage, chemotherapy)
 of esophageal cancer (*see under* Esophagus, cancer)
 of esophageal carcinoma (*see under* Esophagus, carcinoma)
 of gastric cancer (*see under* Gastric cancer)
 in gastrointestinal tract cancer, upper, postoperative, Sept./Oct. 250
 in lung cancer (*see* Lung cancer, non-small cell, chemotherapy of)
 in marrow transplant (*see* Marrow transplant, chemotherapy)

Chest symptoms: in lung cancer, Mar./Apr. 75-77

Chromosome changes: in lung cancer, Mar./Apr. 71

Cisplatin-based regimens: in lung cancer, May/June 130-131

Colon: cancer, CEA elevation in, Nov/Dec. 308

Cranial radiotherapy: prophylactic, in lung cancer, May/June 126

Cryopreservation
 general principles, Jan./Feb. 10-11
 quality of, Jan./Feb. 10

Cyclophosphamide: in marrow transplant, Jan./Feb. 12-13

Cystitis: hemorrhagic, after marrow transplant, Jan./Feb. 44

Cytologic smears: of sputum, in lung cancer detection, Mar./Apr. 80

Cytomegalovirus: after marrow transplant, Jan./Feb. 39

Cytotoxic drugs: in marrow transplant, Jan./Feb. 12-14

D

Diet: and lung cancer, Mar./Apr. 69

DNA ploidy: in breast cancer, July/Aug. 176-178

Drugs: cytotoxic, in marrow transplant, Jan./Feb. 12-14

DuPAN-2: as tumor marker, Nov./Dec. 326

Dysphagia: in esophageal carcinoma, palliative techniques for, Sept./Oct. 267-268

E

EAP: in gastric cancer, Sept./Oct. 280

Epstein-Barr virus B-cell lymphoma after marrow transplant, Jan./Feb. 40-41

Endocrine
 dysfunction after marrow transplant, Jan./Feb. 44
 therapy in breast cancer (*see* Breast cancer, early stage, endocrine treatment)

Enolase: neuron specific, as tumor marker, Nov./Dec. 329

Enzyme markers: in oncology, Nov./Dec. 328-331

Esophagus, cancer
 carboplatin in, Sept./Oct. 259
 chemotherapy
 combination, Sept./Oct. 258
 single agent, Sept./Oct. 254-257
 definition of TNM, Sept./Oct. 243
 failure pattern, autopsy data, Sept./Oct. 246
 metastases, sites of, Sept./Oct. 246
 Esophagus, carcinoma, Sept./Oct. 252-268
 chemotherapy, Sept./Oct. 253-260
 combination, Sept./Oct. 257-260
 drug regimen choice, Sept./Oct. 261
 with radiotherapy, Sept./Oct. 263-266
 surgery after, Sept./Oct. 261-263
 combined modality therapy, Sept./Oct. 261
 toxicities with, additive, Sept./Oct. 261
 dysphagia in, palliative techniques for, Sept./Oct. 267-268

Esophagus (*cont.*)

- interferon with fluorouracil in, Sept./Oct. 260
- Intergroup Trial, Sept./Oct. 266–268
- neoadjuvant therapy, Sept./Oct. 260–268
- radiotherapy of, Sept./Oct. 253
 - with chemotherapy, Sept./Oct. 263–266
 - preoperative, Sept./Oct. 260–261
- response assessment, Sept./Oct. 254
- surgery, Sept./Oct. 252–253
 - with preoperative chemotherapy, Sept./Oct. 261–263
- treatment, Sept./Oct. 252–268

F

- FAMTX: in gastric cancer, Sept./Oct. 281
- α -Fetoprotein (*see* Alpha-fetoprotein)
- Fiberoptic bronchoscopy: in lung cancer detection, Mar./Apr. 81–82
- Fluorouracil: with interferon in esophageal carcinoma, Sept./Oct. 260

G

- Gastric cancer, Sept./Oct. 268–282
 - adjuvant therapy, Sept./Oct. 268–273
 - advanced, Sept./Oct. 273–282
 - chemotherapy, combination, Sept./Oct. 275–282
 - chemotherapy of, single agent, Sept./Oct. 273–275
 - chemotherapy, intraperitoneal, Sept./Oct. 271–273
 - definition of TNM, Sept./Oct. 244
 - EAP in, Sept./Oct. 280
 - FAMTX in, Sept./Oct. 281
 - metastases, sites of, Sept./Oct. 247
- Gastrointestinal tract cancer, upper, Sept./Oct. 239–293
 - abstract, Sept./Oct. 239

adjuvant therapy

- choosing appropriate patient, Sept./Oct. 249–250
 - postoperative, timing of, Sept./Oct. 252
 - rationale for, Sept./Oct. 248–252
 - site of primary, Sept./Oct. 248–249
 - chemotherapy, postoperative, Sept./Oct. 250
 - epidemiology, changing, 240–241
 - failure pattern, Sept./Oct. 245–248
 - prognostic variables, Sept./Oct. 243–245
 - screening, Sept./Oct. 241–242
 - staging, Sept./Oct. 242–243
 - surgical procedure employed, type of, Sept./Oct. 250–252
 - survival by stage, Sept./Oct. 251
 - treatment, Sept./Oct. 239–293
- Gene
- p53, abnormalities in lung cancer, Mar./Apr. 72
 - rb, in lung cancer, Mar./Apr. 72
- Genetic
- alterations in breast cancer, July/Aug. 178–181
 - lesions in lung cancer, Mar./Apr. 69–74
- Germ cell tumors, Nov./Dec. 316
- Glycoprotein(s)
- mucin epitopes and Lewis antigens, Nov./Dec. 321
 - mucinous, as tumor marker, Nov./Dec. 320–328
 - tumor markers, Nov./Dec. 304–320
- Gonadotropin, beta-human chorionic, Nov./Dec. 313–317
- in germ cell tumors, Nov./Dec. 316
- Graft: hematopoietic stem cell, in marrow transplant, Jan./Feb. 9
- Growth regulatory system: in lung cancer, Mar./Apr. 72–73

H

- Hematological cancer: marrow transplant in, Jan./Feb. 19–33

Hematopoietic
 reconstitution, methods, Jan./Feb. 7
 stem cell (see Marrow transplant,
 hematopoietic stem cell)
 Hemorrhagic cystitis: after marrow
 transplant, Jan./Feb. 44
 Herpes simplex: after marrow trans-
 plant, Jan./Feb. 38-39
 Hodgkin's disease
 marrow transplant in, Jan./Feb.
 25-28
 results, Jan./Feb. 23, 28
 relapsed and refractory, condi-
 tioning regimens for, Jan./
 Feb. 26
 Hormone(s)
 in breast cancer (see Breast can-
 cer, early stage, hormone in)
 chemohormonal treatment in
 breast cancer, July/Aug. 207-
 210
 receptor assays, comparison of,
 July/Aug. 172
 therapy in breast cancer; toxicity
 of, July/Aug. 211-213
 as tumor markers, Nov./Dec. 331-
 334

I

Ifosfamide: in marrow transplant,
 Jan./Feb. 13
 Immune system molecules: as tu-
 mor markers, Nov./Dec. 334-
 338
 Immunoglobulins: as tumor mark-
 ers, Nov./Dec. 334-335
 Interferon: with fluorouracil in
 esophageal carcinoma, Sept./
 Oct. 260
 Irradiation (see Radiotherapy)

K

Kaplan-Meier survival curves: in
 myeloma, Nov./Dec. 336

L

Lactic acid dehydrogenase: as tu-
 mor marker, Nov./Dec. 330

Leukemia: marrow transplant in,
 Jan./Feb. 28-32
 Lewis antigens: and mucin-
 glycoprotein epitopes, Nov./
 Dec. 321
 Liver toxicity: in marrow transplant,
 Jan./Feb. 41-43
 Lung
 adenocarcinoma, Mar./Apr. 85-86
 cancer (see below)
 carcinoma
 large cell, Mar./Apr. 86
 squamous cell, Mar./Apr. 85
 stem cells in lung cancer, Mar./
 Apr. 84-85
 toxicity and marrow transplant,
 Jan./Feb. 41
 Lung cancer, non-small cell, Mar./
 Apr. 65-104, May/June 109-
 154
 abstract, Mar./Apr. 65-67
 allele losses at multiple sites,
 Mar./Apr. 71
 asbestos and, Mar./Apr. 68-69
 biopsy in, percutaneous fine-
 needle aspiration, Mar./Apr.
 82-83
 bronchoscopy in, fiberoptic, Mar./
 Apr. 81-82
 carcinogens in, Mar./Apr. 68-69
 chemotherapy, May/June 126,
 127-142
 administration principles, May/
 June 128-134
 combination, May/June 129-134
 combination, cyclic alternating
 May/June 132
 dose-response relationships,
 May/June 131-132
 duration of, May/June 132-133
 morbidity and mortality after,
 May/June 134-135
 perspective on, May/June 141-
 142
 preoperative, May/June 138-
 139, 140
 prognostic factors with, May/
 June 133-134
 with radiotherapy, May/June
 137-138

Lung cancer (*cont.*)

- response assessment, May/June 128
- results, May/June 135-141
- selection of patients, May/June 127-128
- single-agent, May/June 128-129
- single agent, efficacy of, May/June 130
- with surgery, May/June 139-141
- survival and response in, May/June 133
- chest symptoms in, Mar./Apr. 75-77
- chromosomal changes in, Mar./Apr. 71
- cisplatin-based regimens in, efficacy, May/June 130-131
- clinical features, Mar./Apr. 74-78
- detection, early, Mar./Apr. 78-81
 - with biochemical markers, Mar./Apr. 80
- detection, immunohistochemical, from sputum cytologic smears, Mar./Apr. 80
- diagnosis, pathologic, Mar./Apr. 81-83
- diet and, Mar./Apr. 69
- etiology, Mar./Apr. 67-74
- genetic lesions in, Mar./Apr. 69-74
- growth regulatory system in, Mar./Apr. 72-73
- histologic types, frequency of, Mar./Apr. 84
- histopathologic events in, early, Mar./Apr. 84-85
- investigational approaches to tumor reduction, May/June 142-143
- metastases in
 - cerebral solitary, May/June 117
 - outside thorax, Mar./Apr. 77
- microscopic tumor at bronchial margin, resection results, May/June 117
- mutations in
 - number and timing, Mar./Apr. 73
- ras, Mar./Apr. 70

- neuroendocrine features, Mar./Apr. 86
- nicotine in, Mar./Apr. 72-73
- occult
 - identification of, Mar./Apr. 80-81
 - resection results in, May/June 115
- oncogenes in
 - dominant, Mar./Apr. 70-71
 - recessive, Mar./Apr. 71-74
- operability determination, May/June 112-113
- opioids in, Mar./Apr. 72-73
- paraneoplastic syndromes in, Mar./Apr. 77
- pathogenesis
 - molecular, Mar./Apr. 69-74
 - stages in, Mar./Apr. 84-85
- pathology, Mar./Apr. 83-86
- pericardial effusion in, Mar./Apr. 76
- p53 gene abnormalities in, Mar./Apr. 72
- pleural effusion in, malignant, Mar./Apr. 76
- predisposition to, inherited, Mar./Apr. 73-74
- prognostic factors, Mar./Apr. 86-92
- radiotherapy in, May/June 118-127
 - adjuvant, May/June 125-127
 - with chemotherapy, May/June 137-138
- combination, contradictory effects of, May/June 134
- cranial, prophylactic, May/June 126
- definitive, May/June 118-125
- definitive, dose, May/June 120-121
- definitive, selection of patients, May/June 119
- definitive, survival effects of, May/June 123-124
- definitive, treatment volume, May/June 119-120
- failure patterns, May/June 124-125

fractionation, May/June 120-122
 morbidity of, May/June 122
 palliative, May/June 126-127
 postoperative, May/June 125
 preoperative, May/June 125
 results, May/June 122-123
 in stage IV, May/June 126
 survival with, May/June 122-123
 techniques undergoing clinical evaluation, May/June 121-122
 radon and, Mar./Apr. 68-69
 rb gene in, Mar./Apr. 72
 resection results in, May/June 115-117
 screening for, Mar./Apr. 78-81
 clinical trials, Mar./Apr. 79-80
 smoking and, Mar./Apr. 68-69
 stage I
 radiotherapy results in, May/June 123
 resection results in, May/June 115
 stage II
 radiotherapy results, May/June 123
 resection results in, May/June 115
 stage IIIa, resection results in, May/June 116-117
 stage IV, radiotherapy and chemotherapy in, May/June 126
 staging, Mar./Apr. 86-92
 evaluation, Mar./Apr. 89-91
 techniques, Mar./Apr. 89-91
 TNM system, Mar./Apr. 87-88
 stem cells in, pulmonary, Mar./Apr. 84-85
 sulcus tumors, superior, May/June 123
 surgery of, May/June 112-118
 with chemotherapy, May/June 139-141
 failure patterns, May/June 117-118
 morbidity and mortality of, May/June 114-115
 procedures, May/June 113-114

survival by stage, Mar./Apr. 83
 treatment, May/June 109-154
 abstract, May/June 109-111
 palliative, May/June 143-144
 vena cava syndrome in, superior, Mar./Apr. 76
 Lung cancer: small cell, marrow transplant in, Jan./Feb. 33
 Lymphoma
 Epstein-Barr virus B cell, after marrow transplant, Jan./Feb. 40-41
 marrow transplant in, Jan./Feb. 21-25
 results, Jan./Feb. 23

M

Malignancy (*see* Cancer)
 Marrow transplant, Jan./Feb. 5-57
 abstract, Jan./Feb. 5
 in breast cancer, Jan./Feb. 35-36
 carboplatin in, Jan./Feb. 13
 chemotherapy
 intensive, role of, Jan./Feb. 6-9
 single agent dose escalation, Jan./Feb. 8
 complications, Jan./Feb. 37-44
 cryopreservation in, Jan./Feb. 10-11
 cyclophosphamide in, Jan./Feb. 12-13
 cystitis after, hemorrhagic, Jan./Feb. 44
 cytomegalovirus after, Jan./Feb. 39
 cytotoxic drugs in, Jan./Feb. 12-14
 endocrine dysfunction after, Jan./Feb. 44
 engraftment
 delay in, Jan./Feb. 43
 effect of infections on, Jan./Feb. 40
 future directions, Jan./Feb. 44-46
 in hematological cancer, Jan./Feb. 19-33
 biological observations, Jan./Feb. 19-21
 hematopoietic engraftment in, Jan./Feb. 31

Marrow transplant (*cont.*)
 hematopoietic stem cell(s)
 graft, Jan./Feb. 9
 storage, Jan./Feb. 9-11
 herpes simplex after, Jan./Feb.
 38-39
 high-dose therapy, principles of,
 Jan./Feb. 11-16
 history, Jan./Feb. 5-9
 in Hodgkin's disease, Jan./Feb.
 25-28
 results, Jan./Feb. 23, 28
 ifosfamide in, Jan./Feb. 13
 infections after, Jan./Feb. 37-41
 in leukemia, Jan./Feb. 28-32
 liver toxicity after, Jan./Feb. 41-43
 in lung cancer, small cell, Jan./
 Feb. 33
 in lymphoma, Jan./Feb. 21-25
 results, Jan./Feb. 23
 lymphoma after, Epstein-Barr vi-
 rus B-cell, Jan./Feb. 40-41
 melphalan in, Jan./Feb. 13-14
 in neuroblastoma, Jan./Feb.
 33-34
 in ovarian cancer, Jan./Feb. 36
 purging in, Jan./Feb. 17-19
 methods, Jan./Feb. 18
 radiotherapy and, Jan./Feb. 14-16
 rationale, Jan./Feb. 5-6
 in solid tumors, Jan./Feb. 33-36
 in testicular cancer, Jan./Feb. 34-35
 thiotepa in, Jan./Feb. 13
 toxicity in
 lung, Jan./Feb. 41
 vascular, Jan./Feb. 43
 Melphalan: in marrow transplant,
 Jan./Feb. 13-14
 Metastases
 of breast cancer, July/Aug. 166-169
 cerebral metastasis, solitary, in
 lung cancer, May/June 117
 in esophageal cancer, sites, Sept./
 Oct. 246
 of gastric cancer, sites of, Sept./
 Oct. 247
 of lung cancer (*see* Lung cancer,
 metastases)
 Model: of therapeutic outcome,
 Jan./Feb. 12

Morbidity in lung cancer
 with chemotherapy, May/June
 134-135
 radiotherapy, May/June 122
 surgery, May/June 114-115
 Mortality in lung cancer
 with chemotherapy, May/June
 134-135
 surgery, May/June 114-115
 Mucin-glycoprotein epitopes: and
 Lewis antigens, Nov./Dec. 321
 Mutations (*see* Lung cancer, muta-
 tions in)
 Myeloma: Kaplan-Meier survival
 curves in, Nov./Dec. 336

N

Neuroblastoma: marrow transplant
 in, Jan./Feb. 33-34
 Neuroendocrine features: of lung
 cancer, Mar./Apr. 86
 Neuron specific enolase: as tumor
 marker, Nov./Dec. 329
 Nicotine: in lung cancer, Mar./Apr.
 72-73

O

Oncogenes
 in breast cancer, July/Aug. 178-
 181
 in lung cancer (*see* Lung cancer,
 non-small cell, oncogenes in)
 Oncology, tumor markers in (*see*
 Tumor markers in oncology)
 Opioids: in lung cancer, Mar./Apr.
 72-73
 Outcome: therapeutic, model of,
 Jan./Feb. 12
 Ovarian cancer: marrow transplant
 in, Jan./Feb. 36

P

Pancreas, cancer, CA 19-9 in, Nov./
 Dec. 325
 Paraneoplastic syndromes: in non-
 small cell lung cancer, Mar./
 Apr. 77

Pericardial effusion: in lung cancer, Mar./Apr. 76

p53 gene: abnormalities in lung cancer, Mar./Apr. 72

Placental alkaline phosphatase: as tumor marker, Nov./Dec. 330-331

Pleural effusion: malignant, in lung cancer, Mar./Apr. 76

Pregnancy: during breast cancer, July/Aug. 174-176

Prostate
acid phosphatase as tumor marker, Nov./Dec. 328-329
specific antigen as tumor marker, Nov./Dec. 318-320

R

Radiotherapy
of esophageal carcinoma, Sept./Oct. 253
with chemotherapy, Sept./Oct. 263-266
preoperative, Sept./Oct. 260-261
of lung cancer (see Lung cancer, non-small cell, radiotherapy in)
marrow transplant and, Jan./Feb. 14-16

Radon: and lung cancer, Mar./Apr. 68-69

ras mutations: in lung cancer, Mar./Apr. 70

rb gene: in lung cancer, Mar./Apr. 72

S

Smoking: and lung cancer, Mar./Apr. 68-69

Solid tumors: marrow transplant in, Jan./Feb. 33-36

Stem cells
hematopoietic (see Marrow transplant hematopoietic stem cell)
of lung, in lung cancer, Mar./Apr. 84-85

Stomach (see Gastric)

T

Tamoxifen in breast cancer, July/Aug. 202-207, 210-211
trials, July/Aug. 203

Testicular cancer: marrow transplant in, Jan./Feb. 34-35

Therapeutic outcome: model of, Jan./Feb. 12

Thiotepa: in marrow transplant, Jan./Feb. 13

Thoracic symptoms: in lung cancer, Mar./Apr. 75-77

Thyroglobulin: as tumor marker, Nov./Dec. 331-333

Tissue polypeptide antigen: as tumor marker, Nov./Dec. 317

Toxicity
of chemotherapy in breast cancer, July/Aug. 198-200
of hormonal therapy in breast cancer, July/Aug. 211-213
liver, after marrow transplant, Jan./Feb. 41-43
lung, in marrow transplant, Jan./Feb. 41
vascular, after marrow transplant, Jan./Feb. 43

Transplantation, marrow (see Marrow transplant)

Tumor(s)
germ cell, Nov./Dec. 316
markers in oncology (see below)
solid, marrow transplant in, Jan./Feb. 33-36

Tumor markers in oncology, Nov./Dec. 301-350
abstract, Nov./Dec. 301
alkaline phosphatase, placental, Nov./Dec. 330-331
alpha-fetoprotein, Nov./Dec. 313-317
beta-2-microglobulin, Nov./Dec. 335-338

CA 15-3, Nov./Dec. 322
CA 19-9, Nov./Dec. 324-326
CA 50, Nov./Dec. 324-326
CA 125, Nov./Dec. 327-328
CA 195, Nov./Dec. 326-327
calcitonin, Nov./Dec. 331

Tumor markers in oncology (*cont.*)
cancer antigen, mucinous-like,
Nov/Dec. 323-324
carcinoembryonic antigen, Nov/
Dec. 304-313
carcinoma antigen, squamous
cell, Nov/Dec. 318
catecholamines, Nov/Dec. 333-
334
classification of, Nov/Dec. 302-
303
DuPAN-2, Nov/Dec. 326
enolase, neuron-specific, Nov/
Dec. 329
enzyme, Nov/Dec. 328-331
following treatment course, Nov/
Dec. 338
glycoprotein, Nov/Dec. 304-320
mucinous, Nov/Dec. 320-328
gonadotropin, beta-human chori-
onic, Nov/Dec. 313-317
hormones, Nov/Dec. 331-334
immune system molecules, Nov/
Dec. 334-338
immunoglobulins, Nov/Dec. 334-
335

lactic acid dehydrogenase, Nov/
Dec. 330
major, summary of, Nov./Dec. 337
prostate specific antigen, Nov/
Dec. 318–320
prostatic acid phosphatase, Nov/
Dec. 328–329
thyroglobulin, Nov./Dec. 331–333
tissue polypeptide antigen, Nov/
Dec. 317
use of, clinical, Nov./Dec. 301–350

V

Vena cava syndrome: superior, in lung cancer, Mar./Apr. 76
Vessels: toxicity after marrow transplant, Jan./Feb. 43
Viruses
 cytomegalovirus after marrow transplant, Jan./Feb. 39
 Epstein-Barr, B-cell lymphoma after marrow transplant, Jan./Feb. 40-41
 herpes simplex after marrow transplant, Jan./Feb. 38-39

[illegible]

